Docetaxel with prednisone or prednisolone for the treatment of ...

1. Cancer Research UK. CancerStats incidence – UK
[web page on the Internet]. London: Cancer Research
UK; 2004.URL: http://info.cancerresearchuk.org/
cancerstats/incidence/. Accessed July 2005.
2. Cancer Research UK. CancerStats mortality – UK
[web page on the Internet]. London: Cancer Research
UK; 2004. URL: http://info.cancerresearchuk.org/
cancerstats/mortality/. Accessed July 2005.
3. Office for National Statistics. Cancer survival: cancer
survival trends by NHS region, selected cancers, patients
diagnosed 1971–90: age-standardised relative survival
rates (with 95% confidence intervals) at one and five
years after diagnosis, and average increases in relative
survival [web page on the Internet]. London: Office
for National Statistics; 2002. URL:
http://www.statistics.gov.uk/StatBase/xsdataset.asp?
More=Y&vlnk=977&All=Y&B2.x=72&B2.y=13.
Accessed 18 January 2005.
4. Department of Health. Hospital episode statistics
2003–2004 [pdf on the Internet]. London:
Department of Health; 2004. URL:
http://www.dh.gov.uk/assetRoot/04/09/70/20/040970
20.pdf. Accessed 18 January 2005.
5. Gronberg H. Prostate cancer epidemiology. Lancet
2003;361:859–64.
6. Shaneyfelt T, Husein R, Bubley G, Mantzoros.
Hormonal predictors of prostate cancer: a metaanalysis.
J Clin Oncol 2000;18:847–53.
7. Deutsch E, Maggiorella L, Eschwege P, Bourhis J,
Soria JC, Abdulkarim B. Environmental, genetic,
and molecular features of prostate cancer. Lancet
Oncol 2004;5:303–13.
8. National Institute for Clinical Excellence. Guidance
on cancer services: improving outcomes in urological
cancers: the manual. London: NICE; 2002.
9. Muthuramalingam SR, Patel K, Protheroe A.
Management of patients with hormone refractory
prostate cancer. Clin Oncol (R Coll Radiol)
2004;16:505–16.
10. Coleman MP, Rachet B, Woods LM, Mitry E,
Riga M, Cooper N, et al. Trends and
socioeconomic inequalities in cancer survival in
England and Wales up to 2001. Br J Cancer
2004;90:1367–73.
11. Chamberlain J, Melia J, Moss S, Brown J. The
diagnosis, management, treatment and costs of
prostate cancer in England and Wales. Health
Technol Assess 1997;1(3).
References
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
Health Technology Assessment 2007; Vol. 11: No. 2
12. Eisenberger MA, Blumenstein BA, Crawford ED,
Miller G, McLeod DG, Loehrer PJ, et al. Bilateral
orchiectomy with or without flutamide for
metastatic prostate cancer. N Engl J Med
1998;339:1036–42.
13. Petrylak DP. Chemotherapy for androgenindependent
prostate cancer. Semin Urol Oncol
2002;20 (3 Suppl 1):31–5.
14. Vaishampayan U, Parchment RE, Jasti BR,
Hussain M. Taxanes: an overview of the
pharmacokinetics and pharmacodynamics. Urology
1999;54 Suppl 6A:22–9.
15. Stein CA. Mechanisms of action of taxanes in
prostate cancer. Semin Oncol 1999;26(5 Suppl
17):3–7.
16. Aventis Pharma. Taxotere [summary of product
characteristics]. Electronic Medicines Compendium;
2004. URL: http://emc.medicines.org.uk/emc/
assets/c/html/displaydoc.asp?documentid=4594.
Accessed 6 January 2005.
17. The Royal College of Radiologists’ Clinical
Oncology Information Network, British
Association of Urological Surgeons. Guidelines on
the management of prostate cancer. Clin Oncol (R
Coll Radiol) 1999;11:S53–88.
18. Joint Formulary Committee. British National
Formulary. 49th ed. [book on the Internet]. London:
British Medical Association and Royal
Pharmaceutical Society of Great Britain; 2005.
URL: http://www.bnf.org/bnf/. Accessed 15 August
2005.
19. National Horizon Scanning Centre. Docetaxel for
hormone-refractory prostate cancer [pdf on the Internet].
Birmingham: National Horizon Scanning Centre;
2003. URL: http://www.pcpoh.bham.ac.uk/
publichealth/horizon/PDF_files/2003reports/doceta
xel.pdf. Accessed 20 April 2005.
20. Center for Drug Evaluation and Research. Approval
package for Novantrone. Application number
019297/S014 [pdf on the Internet]. Center for Drug
Evaluation and Research; 1996. URL:
http://www.fda.gov/cder/foi/nda/96/019297_s014ap.
pdf. Accessed 26 May 2005.
21. PDR drug information for Novantrone for injection
concentrate [web page on the Internet]. URL:
http://www.drugs.com/pdr/mitoxantrone_
hydrochloride.html. Accessed 24 August 2005.
22. Pharmacia Limited. Estracyt capsules [summary of
product characteristics]. Electronic Medicines
83